Results 151 to 160 of about 1,481 (180)

Esketamine Nasal Spray vs Quetiapine Extended-Release

The Journal of Clinical Psychiatry
Objective: This post hoc analysis of the ESCAPE-TRD trial compared work productivity loss (WPL) and related costs among patients with treatment-resistant depression (TRD) receiving esketamine nasal spray or quetiapine extended release in combination with an oral antidepressant.
Kristin, Clemens, Amanda, Teeple, Maryia, Zhdanava, Aditi, Shah, Kruti, Joshi, Jozefien, Buyze, Dominic, Pilon, Hannah E, Bowrey, Yordan, Godinov   +8 more
openaire   +2 more sources

Esketamine Nasal Spray: new hope for the rapid reduction of depressive symptoms? Review article

2022
A perturbação depressiva major (PDM) é uma doença psiquiátrica comum com um impacto devastador em todos os aspetos da vida. Aproximadamente, 30% dos doentes com esta perturbação não atingem a remissão apesar do tratamento com pelo menos dois antidepressivos orais e, portanto, são considerados como tendo depressão resistente ao tratamento (DRT). A PDM é
openaire   +2 more sources

Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials

Clinical Pharmacology & Therapeutics
Despite being approved by the US FDA and the EU European Medicines Agency, the performance of esketamine nasal spray as an adjunctive therapy with an antidepressant in major depressive disorder is still controversial. Comprehensive retrieval in Embase, Pubmed, and Web of Science was conducted to identify randomized controlled trials comparing ...
Zhibin Wang, Lili Jiang, Wenzhuang Ma, Xingyue Li, Qiushi Gao, Siyu Lian, Weiwei Yu   +6 more
openaire   +2 more sources

Cost Efficiency of Esketamine Nasal Spray Versus Quetiapine for Treatment Resistant Depression

CNS Spectrums
ObjectiveTo compare the per-patient direct and indirect costs associated with achieving remission with esketamine nasal spray plus oral antidepressants (ESK NS+OAD) versus quetiapine extended release plus oral antidepressants (QTP XR+OAD) among patients with treatment-resistant depression (TRD).
Kristin Clemens, Amanda Teeple, Benoit Rive, Noam Kirson, Urvi Desai, Jason Doran, Dody Eid, Alice Qu, Hannah Bowrey, Kruti Joshi   +9 more
openaire   +1 more source

Post‐approval analysis finds favorable safety for esketamine nasal spray

The Brown University Psychopharmacology Update
Nearly five years of post‐approval safety data for esketamine nasal spray have uncovered no new safety concerns associated with the formulation, an analysis has found. Most adverse events occurred during the first treatment session, with incidence decreasing over the course of treatment. Results were published online Sept. 10, 2025,
openaire   +1 more source

Analysis of trial confirms efficacy of esketamine nasal spray in TRD

The Brown University Psychopharmacology Update
Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended‐release quetiapine in patients with treatment‐resistant depression (TRD). The additional analyses of the ESCAPE‐TRD trial used multiple thresholds for remission and relapse.
openaire   +1 more source

Esketamine nasal spray shows rapid effects in suicidal patients

The Brown University Psychopharmacology Update, 2021
openaire   +1 more source

Esketamine nasal spray not recommended by NICE

PharmacoEconomics & Outcomes News, 2020
openaire   +1 more source

Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme

International Journal of Psychiatry in Clinical Practice, 2022
Ludovic Samalin, Maud Rothärmel
exaly  

Safety results favorable for esketamine nasal spray for depression

The Brown University Psychopharmacology Update, 2020
openaire   +1 more source